182 related articles for article (PubMed ID: 11689157)
1. Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties.
Boules M; McMahon B; Warrington L; Stewart J; Jackson J; Fauq A; McCormick D; Richelson E
Brain Res; 2001 Nov; 919(1):1-11. PubMed ID: 11689157
[TBL] [Abstract][Full Text] [Related]
2. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.
Cusack B; Boules M; Tyler BM; Fauq A; McCormick DJ; Richelson E
Brain Res; 2000 Feb; 856(1-2):48-54. PubMed ID: 10677610
[TBL] [Abstract][Full Text] [Related]
3. Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier.
Boules M; McMahon B; Wang R; Warrington L; Stewart J; Yerbury S; Fauq A; McCormick D; Richelson E
Brain Res; 2003 Oct; 987(1):39-48. PubMed ID: 14499944
[TBL] [Abstract][Full Text] [Related]
4. Highly potent neurotensin analog that causes hypothermia and antinociception.
Tyler-McMahon BM; Stewart JA; Farinas F; McCormick DJ; Richelson E
Eur J Pharmacol; 2000 Feb; 390(1-2):107-11. PubMed ID: 10708713
[TBL] [Abstract][Full Text] [Related]
5. NT79: A novel neurotensin analog with selective behavioral effects.
Boules M; Liang Y; Briody S; Miura T; Fauq I; Oliveros A; Wilson M; Khaniyev S; Williams K; Li Z; Qi Y; Katovich M; Richelson E
Brain Res; 2010 Jan; 1308():35-46. PubMed ID: 19874804
[TBL] [Abstract][Full Text] [Related]
6. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux.
Prus AJ; Huang M; Li Z; Dai J; Meltzer HY
Brain Res; 2007 Dec; 1184():354-64. PubMed ID: 17988654
[TBL] [Abstract][Full Text] [Related]
7. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.
Li Z; Boules M; Williams K; Peris J; Richelson E
Brain Res; 2010 Jan; 1311():28-36. PubMed ID: 19948149
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA
Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636
[TBL] [Abstract][Full Text] [Related]
9. The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.
Holly EN; Ebrecht B; Prus AJ
Eur Neuropsychopharmacol; 2011 Jul; 21(7):526-31. PubMed ID: 21277173
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
11. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
Jelovac N; Sikiric P; Rucman R; Petek M; Marovic A; Perovic D; Seiwerth S; Mise S; Turkovic B; Dodig G; Miklic P; Buljat G; Prkacin I
Eur J Pharmacol; 1999 Aug; 379(1):19-31. PubMed ID: 10499368
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the role of 5-HT(2) receptor antagonism during subchronic antipsychotic drug administration in rats.
Kruzich PJ; See RE
Brain Res; 2000 Sep; 875(1-2):35-43. PubMed ID: 10967296
[TBL] [Abstract][Full Text] [Related]
13. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier.
Kokko KP; Hadden MK; Price KL; Orwig KS; See RE; Dix TA
Neuropharmacology; 2005 Mar; 48(3):417-25. PubMed ID: 15721174
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.
Bredeloux P; Cavelier F; Dubuc I; Vivet B; Costentin J; Martinez J
J Med Chem; 2008 Mar; 51(6):1610-6. PubMed ID: 18321036
[TBL] [Abstract][Full Text] [Related]
15. Use of amfonelic acid to discriminate between classical and atypical neuroleptics and neurotensin: an in vivo voltammetric study.
Rivest R; Jolicoeur FB; Marsden CA
Brain Res; 1991 Mar; 544(1):86-93. PubMed ID: 1677303
[TBL] [Abstract][Full Text] [Related]
16. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.
Briody S; Boules M; Oliveros A; Fauq I; Richelson E
Behav Brain Res; 2010 Feb; 207(1):118-24. PubMed ID: 19800922
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.
Radke JM; Owens MJ; Ritchie JC; Nemeroff CB
Proc Natl Acad Sci U S A; 1998 Sep; 95(19):11462-4. PubMed ID: 9736759
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin induces catalepsy in mice.
Snijders R; Kramarcy NR; Hurd RW; Nemeroff CB; Dunn AJ
Neuropharmacology; 1982 May; 21(5):465-8. PubMed ID: 6810195
[TBL] [Abstract][Full Text] [Related]
19. Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release.
Osborne PG; O'Connor WT; Beck O; Ungerstedt U
Brain Res; 1994 Jan; 634(1):20-30. PubMed ID: 7908848
[TBL] [Abstract][Full Text] [Related]
20. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity.
Boules M; Warrington L; Fauq A; McCormick D; Richelson E
Eur J Pharmacol; 2001 Aug; 426(1-2):73-6. PubMed ID: 11525773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
